Turtle Beach Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Turtle Beach Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $111.32M | Mar 18, 2019 |
| FY2018 | Sep 30, 2018 | $74.43M | Mar 18, 2019 |
| FY2018 | Jun 30, 2018 | $60.81M | Mar 18, 2019 |
| FY2018 | Mar 31, 2018 | $40.89M | Mar 18, 2019 |
| FY2018 | Dec 31, 2017 | $79.70M | Mar 18, 2019 |
| FY2018 | Sep 30, 2017 | $35.98M | Mar 18, 2019 |
| FY2018 | Jun 30, 2017 | $19.11M | Mar 18, 2019 |
| FY2018 | Mar 31, 2017 | $14.35M | Mar 18, 2019 |
| FY2018 | Dec 31, 2016 | $173.98M | Mar 18, 2019 |
| FY2013 | Sep 30, 2013 | $562.9K | Nov 26, 2013 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $319.91M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $372.77M | Mar 12, 2026 |
| FY2023 | Dec 31, 2023 | $99.54M | Mar 13, 2024 |
| FY2023 | Sep 30, 2023 | $59.16M | Mar 13, 2024 |
| FY2023 | Jun 30, 2023 | $47.98M | Mar 13, 2024 |
| FY2023 | Mar 31, 2023 | $51.44M | Mar 13, 2024 |
| FY2023 | Dec 31, 2022 | $100.90M | Mar 13, 2024 |
| FY2023 | Sep 30, 2022 | $51.30M | Mar 13, 2024 |
| FY2023 | Jun 30, 2022 | $41.30M | Mar 13, 2024 |
| FY2023 | Mar 31, 2022 | $46.66M | Mar 13, 2024 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $79.70M | Mar 7, 2018 |
| FY2017 | Sep 30, 2017 | $35.98M | Mar 7, 2018 |
| FY2017 | Jun 30, 2017 | $19.11M | Mar 7, 2018 |
| FY2017 | Mar 31, 2017 | $14.35M | Mar 7, 2018 |
| FY2017 | Dec 31, 2016 | $82.20M | Mar 7, 2018 |
| FY2017 | Sep 30, 2016 | $38.38M | Mar 7, 2018 |
| FY2017 | Jun 30, 2016 | $29.36M | Mar 7, 2018 |
| FY2017 | Mar 31, 2016 | $24.03M | Mar 7, 2018 |
| FY2016 | Dec 31, 2015 | $84.56M | Mar 8, 2017 |
| FY2016 | Sep 30, 2015 | $35.89M | Mar 8, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $119.28M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $128.98M | Mar 12, 2026 |
| FY2023 | Dec 31, 2023 | $31.80M | Mar 13, 2024 |
| FY2023 | Sep 30, 2023 | $17.69M | Mar 13, 2024 |
| FY2023 | Jun 30, 2023 | $11.87M | Mar 13, 2024 |
| FY2023 | Mar 31, 2023 | $14.14M | Mar 13, 2024 |
| FY2023 | Dec 31, 2022 | $20.02M | Mar 13, 2024 |
| FY2023 | Sep 30, 2022 | $7.26M | Mar 13, 2024 |
| FY2023 | Jun 30, 2022 | $7.88M | Mar 13, 2024 |
| FY2023 | Mar 31, 2022 | $14.03M | Mar 13, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.73M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $16.18M | Mar 12, 2026 |
| FY2023 | Dec 31, 2023 | $8.55M | Mar 13, 2024 |
| FY2023 | Sep 30, 2023 | ($3.61M) | Mar 13, 2024 |
| FY2023 | Jun 30, 2023 | ($15.92M) | Mar 13, 2024 |
| FY2023 | Mar 31, 2023 | ($6.71M) | Mar 13, 2024 |
| FY2023 | Dec 31, 2022 | ($23.23M) | Mar 13, 2024 |
| FY2023 | Sep 30, 2022 | ($12.01M) | Mar 13, 2024 |
| FY2023 | Jun 30, 2022 | ($17.83M) | Mar 13, 2024 |
| FY2023 | Mar 31, 2022 | ($6.48M) | Mar 13, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.52M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $20.03M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | ($16.44M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | ($51.48M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $20.43M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $49.17M | Mar 29, 2023 |
| FY2021 | Dec 31, 2019 | $10.43M | Mar 2, 2022 |
| FY2020 | Dec 31, 2018 | $54.04M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $4.80M | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | ($77.70M) | Mar 18, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.89M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $17.30M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $17.14M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $19.12M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $17.49M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $12.27M | Mar 29, 2023 |
| FY2021 | Dec 31, 2019 | $7.86M | Mar 2, 2022 |
| FY2020 | Dec 31, 2018 | $5.61M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $5.59M | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | $8.26M | Mar 18, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Sep 30, 2013 | $4.60M | Nov 26, 2013 |
| FY2012 | Sep 30, 2012 | $3.25M | Nov 28, 2012 |
| FY2011 | Sep 30, 2011 | $572.3K | Nov 22, 2011 |
| FY2011 | Sep 30, 2010 | $446.9K | Nov 22, 2011 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.46M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $5.76M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $27.04M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | ($41.85M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | ($327.0K) | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $51.05M | Mar 29, 2023 |
| FY2021 | Dec 31, 2019 | $39.37M | Mar 2, 2022 |
| FY2020 | Dec 31, 2018 | $42.25M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $3.42M | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | ($1.83M) | Mar 18, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.42M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $4.91M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $2.16M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $3.55M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $5.62M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $5.66M | Mar 29, 2023 |
| FY2021 | Dec 31, 2019 | $1.91M | Mar 2, 2022 |
| FY2020 | Dec 31, 2018 | $5.08M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $4.41M | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | $3.23M | Mar 18, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $269.05M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $298.86M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $149.97M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $163.39M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $230.51M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $203.45M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $131.35M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $121.92M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $94.25M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $94.80M | Mar 7, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $140.56M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $178.26M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $64.89M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $74.45M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $89.14M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $87.05M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $67.96M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $84.42M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $116.41M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $115.50M | Mar 7, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $128.50M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $120.60M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $85.08M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $88.94M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $141.37M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $116.40M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $63.39M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $37.50M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($22.16M) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($20.70M) | Mar 7, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.43M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $52.94M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $10.69M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $10.69M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $10.69M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $8.18M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $8.52M | Mar 4, 2021 |
| FY2018 | Dec 31, 2018 | $0 | Mar 18, 2019 |
| FY2017 | Dec 31, 2017 | $0 | Mar 7, 2018 |
| FY2017 | Dec 31, 2016 | $0 | Mar 7, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($102.36M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($118.09M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($134.28M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($116.60M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($57.05M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($74.77M) | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | ($113.52M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($131.46M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($170.05M) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($166.80M) | Mar 7, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.96M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $13.00M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $18.73M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $11.40M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $37.72M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $46.68M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $8.25M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $7.08M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $5.25M | Mar 18, 2019 |
| FY2018 | Dec 31, 2016 | $6.18M | Mar 18, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.71M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $48.96M | Mar 12, 2026 |
| FY2018 | Dec 31, 2018 | $37.39M | Mar 18, 2019 |
| FY2018 | Dec 31, 2017 | $70.27M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $66.88M | Mar 7, 2018 |
| FY2016 | Dec 31, 2015 | $64.81M | Mar 8, 2017 |
| FY2015 | Dec 31, 2014 | $44.56M | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $64.58M | Mar 30, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 12, 2026 |
| FY2023 | Dec 31, 2023 | 0 | Mar 13, 2024 |
| FY2023 | Sep 30, 2023 | 0 | Mar 13, 2024 |
| FY2023 | Jun 30, 2023 | 0 | Mar 13, 2024 |
| FY2023 | Mar 31, 2023 | 0 | Mar 13, 2024 |
| FY2023 | Dec 31, 2022 | (1) | Mar 13, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Mar 13, 2024 |
| FY2023 | Jun 30, 2022 | (1) | Mar 13, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Mar 13, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 12, 2026 |
| FY2023 | Dec 31, 2023 | 0 | Mar 13, 2024 |
| FY2023 | Sep 30, 2023 | 0 | Mar 13, 2024 |
| FY2023 | Jun 30, 2023 | 0 | Mar 13, 2024 |
| FY2023 | Mar 31, 2023 | 0 | Mar 13, 2024 |
| FY2023 | Dec 31, 2022 | (1) | Mar 13, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Mar 13, 2024 |
| FY2023 | Jun 30, 2022 | (1) | Mar 13, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Mar 13, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 19.19M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 19.96M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 17.53M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | 16.57M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | 16.17M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | 15.48M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | 14.49M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | 14.27M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | 12.35M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | 49.25M | Mar 7, 2018 |